Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL I Japan: IDegLira vs IDeg vs Liraglutide in T2D
NCT02607306Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2015
- Primary completion
- Dec 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in HbA1c at 52 weeks. Started Nov 2015; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02607306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607306.